(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile

We are (R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile CAS:459868-73-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile
CAS.NO:459868-73-6
Synonyms:(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile
5-[(2R)-2-aminopropyl]-1-(3-phenylmethoxypropyl)-2,3-dihydroindole-7-carbonitrile
5-[(2R)-2-Aminopropyl]-2,3-dihydro-1-[3-(phenylmethoxy)propyl]-1H-indole-7-carbonitrile
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 539.3±50.0 °C at 760 mmHg
Molecular Formula C22H27N3O
Molecular Weight 349.469
Flash Point 280.0±30.1 °C
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Silodosin(CAS:160970-54-7).

(R)-5-(2-aminopropyl)-1-(3-benzyloxypropyl) indoline-7-carbonitrile


Related News: As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.2-Bromoethyl acetate These include: high-barrier generic drug substances and commonly used generic drug substances.50-85-1 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.4-bromo-2-metilpiridina CAS:22282-99-1 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.This includes chemical APIs.

Related Products
Product Name
NAROACTY CL-140 Cas:68439-51-0 View Details
4-Fluorobutanol View Details
Cupric Sulfate View Details
4-(Trifluoromethoxy)benzoic acid manufacturer perflubron Cas:423-55-2 manufacturer 2-Chlorobenzothiazole manufacturer 7-methoxy-6-(3-morpholin-4-ylpropoxy)-1H-quinazolin-4-one manufacturer Atosiban Acetate manufacturer